Diagnosis and Treatment decision of an IDH-mutant glioma through CSF-based cfDNA sequencing

Clicks: 18
ID: 328330
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #68 of 144 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 144 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Classification of tumors of the central nervous system currently requires tumor tissue analysis for histology and molecular markers, according to the 2021 WHO Classification of Tumors of the Central Nervous System. Cerebrospinal fluid (CSF)-based cell-free DNA (cfDNA) sequencing detects these defining molecular alterations and allows for accurate diagnosis and WHO-analogue tumor classification. We hereby report the case of a female patient with an IDH-mutant glioma, TERT promoter mutant, NEC, in whom IDH1 and TERT promoter mutations were identified in CSF after an initially non-informative tissue histology, then confirmed through tissue-based molecular analysis. The patient was initially treated with vorasidenib, an IDH-inhibitor, that was then switched to a procarbazine-CCNU chemotherapy due to clinical worsening under initial therapy. CSF-based cfDNA sequencing is a promising tool for minimally invasive diagnosis of tumors of the CNS in situations in which tissue biopsy is challenging or non-informative.
Reference Key
openalex_W7212002750 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Eve Fouarge, Rouzbeh Banan, Sebastian Curt Schulz, Martin Jakobs, Marianne Schell, Felix Sahm, Tobias Keßler
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag240
URL
https://doi.org/10.1093/noajnl/vdag240
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.